Home Cart Sign in  
Chemical Structure| 297180-15-5 Chemical Structure| 297180-15-5

Structure of Lipofermata
CAS No.: 297180-15-5

Chemical Structure| 297180-15-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Lipofermata is an inhibitor of fatty acid transport (FATP) with IC50 of 4.84 μM in Caco-2 cells.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Lipofermata

CAS No. :297180-15-5
Formula : C15H10BrN3OS
M.W : 360.23
SMILES Code : O=C1NC2=C(C=C(Br)C=C2)C13SC(C4=CC=CC=C4)=NN3
MDL No. :MFCD00770315
InChI Key :RRBYYBWDUNSVAW-UHFFFAOYSA-N
Pubchem ID :3136622

Safety of Lipofermata

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
primary human adipocytes IC50 39.34 µM 15 minutes To evaluate the efficacy of Lipofermata in inhibiting fatty acid uptake, results showed weaker inhibition in primary human adipocytes. Biochem Pharmacol. 2015 Nov 1;98(1):167-81
hsHepG2 IC50 2.74 µM 15 minutes To evaluate the efficacy of Lipofermata in inhibiting fatty acid uptake, results showed significant inhibition in hsHepG2 cells. Biochem Pharmacol. 2015 Nov 1;98(1):167-81
hsCaco-2 IC50 6.09 µM 15 minutes To evaluate the efficacy of Lipofermata in inhibiting fatty acid uptake, results showed significant inhibition in hsCaco-2 cells. Biochem Pharmacol. 2015 Nov 1;98(1):167-81
rnINS-1E IC50 4.65 µM 15 minutes To evaluate the efficacy of Lipofermata in inhibiting fatty acid uptake, results showed significant inhibition in rnINS-1E cells. Biochem Pharmacol. 2015 Nov 1;98(1):167-81
mmC2C12 IC50 5.67 µM 15 minutes To evaluate the efficacy of Lipofermata in inhibiting fatty acid uptake, results showed significant inhibition in mmC2C12 cells. Biochem Pharmacol. 2015 Nov 1;98(1):167-81
HCC1937 2 μM 48 hours Evaluate the inhibitory effect of Lipofermata on HCC1937 cell proliferation, results showed IC50 values indicating Lipofermata effectively inhibited cell growth J Cancer Res Clin Oncol. 2024 May 16;150(5):258
MCF7 1 μM 48 hours Evaluate the inhibitory effect of Lipofermata on MCF7 cell proliferation, results showed IC50 values indicating Lipofermata effectively inhibited cell growth J Cancer Res Clin Oncol. 2024 May 16;150(5):258
DLD-1 1.0 mM 5 minutes Evaluate the effect of Lipofermata on [123I]BMIPP accumulation in DLD-1 cells, showing significant reduction Int J Mol Sci. 2024 Jul 15;25(14):7747
LS180 1.0 mM 5 minutes Evaluate the effect of Lipofermata on [123I]BMIPP accumulation in LS180 cells, showing significant reduction Int J Mol Sci. 2024 Jul 15;25(14):7747
H441 1.0 mM 5 minutes Evaluate the effect of Lipofermata on [123I]BMIPP accumulation in H441 cells, showing significant reduction Int J Mol Sci. 2024 Jul 15;25(14):7747
HepG2 cells 10 μM various time points (up to 4 hours) To investigate the time-dependent effect of Lipofermata on dihydroceramide synthesis, results showed that VLC-NBD-dihydroceramide synthesis levels decreased over time but reverted to control levels after 4 hours. J Biol Chem. 2022 Apr;298(4):101735
HepG2 cells 10 μM 1 hour To investigate the effect of Lipofermata on dihydroceramide synthesis, results showed that Lipofermata decreased the levels of VLC- and LC-NBD-dihydroceramide synthesis in a concentration-dependent manner. J Biol Chem. 2022 Apr;298(4):101735

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 male mice Oral 300 mg/kg Single dose To evaluate the inhibition of fatty acid absorption by Lipofermata, results showed that oral administration of Lipofermata significantly reduced plasma levels of 13C-oleate. Biochem Pharmacol. 2015 Nov 1;98(1):167-81
Zebrafish BRAFV600E driven transgenic zebrafish melanoma model Intratumoral injection 5 μM Once daily for 5 days To assess the effect of Lipofermata on melanoma growth, results showed Lipofermata significantly reduced melanoma cell growth and lipid content Cancer Discov. 2018 Aug;8(8):1006-1025
C57BL/6 mice Unilateral ureteral obstruction (UUO) model Intraperitoneal injection 50 mg/kg/day Once daily for 7 days To evaluate the effect of FATP2 inhibitor Lipofermata on UUO-induced renal fibrosis. Results showed that Lipofermata significantly reduced renal fibrosis and lipid accumulation. Cell Death Dis. 2020 Nov 20;11(11):994
BALB/c mice Breast cancer model Intraperitoneal injection 2.5 mg/kg Every other day for 2 weeks Evaluate the inhibitory effect of Lipofermata on tumor growth in vivo, results showed Lipofermata significantly inhibited tumor growth J Cancer Res Clin Oncol. 2024 May 16;150(5):258
C57BL/6 mice B16F10 melanoma model Intraperitoneal injection 2.5 mg/kg Once daily for 2 weeks To investigate the effect of FATP2 inhibitor lipofermata on lipid accumulation in MDSCs. Results showed that lipofermata treatment altered lipid species in MDSCs. Data Brief. 2021 Feb 13;35:106882

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.78mL

0.56mL

0.28mL

13.88mL

2.78mL

1.39mL

27.76mL

5.55mL

2.78mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories